



**Notice of Allowability**

Application No.	Applicant(s)	
09/720,934	KORENBERG ET AL.	
Examiner	Art Unit	
MISOOK YU, Ph.D.	1642	

— The MAILING DATE of this communication appears on the cover sheet with the correspondence address—

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTO-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from Issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1.  This communication is responsive to 9/22/2005.
2.  The allowed claim(s) is/are 2-4, 15-17, 19, 20 and 23-31.
3.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a)  All
  - b)  Some\*
  - c)  None
  1.  Certified copies of the priority documents have been received.
  2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3.  Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  
**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

4.  A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5.  CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.
  - (a)  including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached
    - 1)  hereto or 2)  to Paper No./Mail Date \_\_\_\_\_.
  - (b)  including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.


Identifying Indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6.  DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

**Attachment(s)**

1.  Notice of References Cited (PTO-892)
2.  Notice of Draftsperson's Patent Drawing Review (PTO-948)
3.  Information Disclosure Statements (PTO-1449 or PTO/SB/08),  
Paper No./Mail Date 4/11/05
4.  Examiner's Comment Regarding Requirement for Deposit of Biological Material
5.  Notice of Informal Patent Application (PTO-152)
6.  Interview Summary (PTO-413),  
Paper No./Mail Date \_\_\_\_\_.
7.  Examiner's Amendment/Comment
8.  Examiner's Statement of Reasons for Allowance
9.  Other \_\_\_\_\_.

*Misook YU 2-17-06*

MISOOK YU, Ph.D.  
Primary Examiner  
Art Unit: 1642



INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
Form PTO-1449 (Modified)  
(Use several sheets if necessary)

COMPLETE IF KNOWN

Application Number	09/720,834
Confirmation Number	8413
Filing Date	January 2, 2001
First Named Inventor	Julie R. Korenberg
Group Art Unit	1642
Examiner Name	Misook Yu

Sheet 1 of 1 Attorney Docket No. 42778.8007.US01

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		NUMBER	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	T
my	AA	PUCHARCÓS, Carles et al., <i>Alu</i> -splice cloning of human <i>Intersectin</i> (ITSN), a putative multivalent binding protein expressed in proliferating and differentiating neurons and overexpressed in Down syndrome, European Journal of Human Genetics (1999) 7, 704-712.	

EXAMINER

*Brusich* >

DATE CONSIDERED

2-17-06

\*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).



ALLOWED CLAIMS FOR USSN 09/720,934

2. An isolated nucleic acid having the nucleotide sequence set forth in SEQ ID NO: 1.
3. The isolated nucleic acid of claim 2, wherein the nucleic acid is DNA or RNA.
4. The isolated nucleic acid of claim 2, wherein the nucleic acid is cDNA.
15. The isolated nucleic acid of claim 2, wherein the nucleic acid is labeled with a detectable marker.
16. The isolated nucleic acid of claim 15, wherein the detectable marker is a radioactive isotope, a fluorophor or an enzyme.
17. An isolated nucleic acid complementary to the entire sequence of the nucleic acid of claim 2.
19. The isolated nucleic acid of claim 17, wherein the isolated nucleic acid is labeled with a detectable marker.
20. The isolated nucleic acid of claim 19, wherein the marker is a radioactive isotope, a fluorophor or an enzyme.
23. A vector comprising the isolated nucleic acid of claim 2.
24. The vector of claim 23, further comprising a promoter or an expression element linked to the nucleic acid.
25. The vector of claim 23, wherein the promoter comprises a bacterial, yeast, insect or mammalian promoter.

26. The vector of claim 24, wherein the vector is a plasmid, cosmid, yeast artificial chromosome (YAC), BAC, P1, bacteriophage or eukaryotic viral DNA.

27. An isolated host cell containing the vector of claim 23.

28. The isolated host cell of claim 27, wherein the host cell is a prokaryotic or eukaryotic cell.

29. The isolated host cell of claim 28, wherein the eukaryotic cell is a yeast, insect, plant or mammalian cell.

30. A method for producing a polypeptide comprising culturing the host cell of claim 27 under conditions suitable for production of the polypeptide and recovering the polypeptide from the host cell culture.

31. A method of obtaining a polypeptide in purified form comprising:

- (a) introducing the vector of claim 23 into a suitable host cell;
- (b) culturing the resulting cell so as to produce the polypeptide;
- (c) recovering the polypeptide produced in step (b); and
- (d) purifying the polypeptide.